These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 9215842

  • 1. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
    McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabárabara P, Harrap KR, Judson IR.
    J Clin Oncol; 1997 Jul; 15(7):2691-700. PubMed ID: 9215842
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA.
    Anticancer Res; 2003 Jul; 23(3C):2757-65. PubMed ID: 12926110
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
    Kurata T, Tamura T, Sasaki Y, Fujii H, Negoro S, Fukuoka M, Saijo N.
    Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
    [Abstract] [Full Text] [Related]

  • 10. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ, Kelland LR, Boxall FE, Valenti MR, Jones M, Goddard PM, Gwynne J, Harrap KR.
    Cancer Res; 1994 Aug 01; 54(15):4118-22. PubMed ID: 8033145
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM, van Gijn R, Schellens JH, Schot M, Lieverst J, Hillebrand MJ, Schoemaker NE, Porro MG, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1999 Jun 01; 17(6):1906-14. PubMed ID: 10561232
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct 01; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 14. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1999 Jan 01; 5(1):69-75. PubMed ID: 9918204
    [Abstract] [Full Text] [Related]

  • 15. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
    Ricart AD, Sarantopoulos J, Calvo E, Chu QS, Greene D, Nathan FE, Petrone ME, Tolcher AW, Papadopoulos KP.
    Clin Cancer Res; 2009 Jun 01; 15(11):3866-71. PubMed ID: 19458055
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
    O'Dwyer PJ, Hudes GR, Walczak J, Schilder R, LaCreta F, Rogers B, Cohen I, Kowal C, Whitfield L, Boyd RA.
    Cancer Res; 1992 Dec 15; 52(24):6746-53. PubMed ID: 1458462
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
    Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE.
    J Clin Oncol; 1999 Dec 15; 17(12):3822-7. PubMed ID: 10577855
    [Abstract] [Full Text] [Related]

  • 18. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.
    Clin Cancer Res; 2002 Jul 15; 8(7):2157-66. PubMed ID: 12114416
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.
    J Clin Oncol; 1995 Jan 15; 13(1):210-21. PubMed ID: 7799022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.